Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


PolyTherics and Celtic Pharma sign Collaboration Agreement to explore technologies for improved drug

PolyTherics Limited (“PolyTherics”), a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, and Celtic Pharma Development Services Bermuda Ltd (“Celtic Pharma”), a subsidiary of Celtic Pharmaceutical Holdings LP, a global private equity investment fund focused on the biopharma industry, today announced that they have entered into a broad research collaboration agreement. Under the terms of the agreement, PolyTherics’ proprietary drug modification technologies will be used to enhance certain of the innovative pharmaceutical products being developed by Celtic Pharma.

The parties plan jointly to develop and validate modifications of drugs submitted to the collaboration by Celtic Pharma, in order to improve their performance and assess their future development potential.

PolyTherics has substantial expertise in the targeted and selective modification of compounds for therapeutic and diagnostic application. Through the application of a platform of polymer-based technologies, it is developing compounds as drug candidates in both existing and emerging markets. With the growing commercial impact of biopharmaceutical products, and particularly next generation antibody fragments, PolyTherics is strongly positioned to address these opportunities. PolyTherics has revenue-generating research and development contracts in place with several companies and is in discussion with a number of others.

Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “We view collaboration through partnership as fundamental to exemplifying the development potential of our proprietary technologies and fulfilling our strategy. The opportunity to collaborate with a high calibre, product-focused company such as Celtic Pharma is a significant milestone in the development of PolyTherics, and we are delighted to be working with Celtic Pharma on several of the products in their portfolio. We believe that our work together will show that PolyTherics’ proprietary technologies can be used to improve pharmaceutical products to increase their commercial value.”

Celtic Pharma currently has a portfolio of nine novel pharmaceutical products in clinical development across a range of therapeutic areas. Each product is being developed to address important unmet medical needs, and Celtic Pharma aims to move these products rapidly and effectively through clinical development to regulatory approval.

Dr Bill Henry, Managing Director - Global Head of CMC at Celtic Pharma, said: “We are excited about accessing the technology capability of PolyTherics through collaboration and exploring its potential impact on our product pipeline.”

- ENDS -
Editors Notes
Press enquiries to: Margaret Henry, PR Consultant.
Tel: +44 (0)1865 811199 E-mail:

Image available on request
Interferon alpha pegylated using the innovative TheraPEG™ technology developed by PolyTherics.

About PolyTherics Ltd
Founded in 2002, PolyTherics is a spin-out company from Imperial College London and the London School of Pharmacy that is dedicated to using biomedical polymers to optimise pharmaceuticals for the treatment and cure of the world's most important diseases.

PolyTherics has developed and patented an innovative approach to PEGylation, known as TheraPEG™, to prolong the half-life of proteins for use in drug development. PEGylation is the process by which Polyethylene Glycol (PEG) is attached to proteins and peptides to modify their pharmacokinetic properties for therapeutic application.

PEGylation increases the time that a compound remains in the bloodstream before being metabolised or excreted by the body, thereby improving its half-life and potentially reducing treatment frequency, decreasing side effects and improving patient compliance. For example, PEGylated interferon treatments for Hepatitis C can be administered once rather than three times per week.

PolyTherics received initial fund

Publisher Contact Information:

PolyTherics, Ltd.
+44 (0)1865 811199

Company profile of PolyTherics, Ltd.
Past press releases of PolyTherics, Ltd. .


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Oct 19€3.0MInternet services
Oct 19€6.0MBusiness applications
Oct 18€11.0MConsumer electronics
Oct 18€5.0MBusiness applications
Oct 17€5.9MBiopharmaceuticals
Oct 16€3.7MContent management
Oct 16€7.8MSensors

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.